Skip to main content

Table 6 Blood–CSF barrier function, CSF albumin, CSF total protein, and CSF L-lactate in MOG-IgG-positive EM

From: Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients

 

Units

Total

Attack

Remission

Acute MY subgroup

Acute ON subgroup

Acute BRAIN subgroup

Blood–CSF barrier function

 QAlb > QAlb(lim)

Samples

36/79 (45.6%)

36/71 (50.7%)

0/6 (0%)

15/23 (65.2%)

6/21 (28.6%)

15/27 (55.6%)

 QAlb, all LPs

–

4 (1.8–15; 78)

4.5 (1.8–15; 70)

3.3 (2.6–3.7; 6)

6 (1.8–11.5; 23)

3.2 (1.9–11.6; 20)

4.6 (1.9–15; 27)

 QAlb, if positive

–

6.9 (4.52–15.04; 35)

6.9 (4.52–15.04; 35)

0 (0–0; 0)

8 (4.5–11.5; 15)

5.1 (4.6–11.6; 5)

6.7 (4.5–15; 15)

 Alb CSF

mg/l

186 (76.8–624; 78)

198 (76.8–624; 70)

131.5 (113–161; 6)

237 (76.8–572; 23)

143 (82–520; 19)

198 (77–624; 28)

 Alb serum

g/l

43.35 (30.5–53.9; 78)

43.4 (30.5–53.9; 70)

42.6 (36–45.3; 6)

43.4 (32–53.8; 25)

44 (37.3–48.5; 19)

42.2 (30.5–53.9; 26)

 Albumin–cellular dissociation

Samples

8/36 (22.2%)

8/36 (22.2%)

0/0 (0%)

1/15 (6.7%)

4/6 (66.7%)

3/15 (20%)

 Combined intrathecal IgG

 synthesis and BCB disruption

Samples

7/36 (19.4%)

7/36 (19.4%)

0/0 (0%)

6/15 (40%)

0/6 (0%)

1/15 (6.7%)

CSF total protein

 CSF TP, all LPs

mg/dl

30.95 (10–97.2; 98)

32.2 (13.4–97.2; 87)

22.1 (10–56.6; 9)

42.1 (14–89; 28)

25.6 (13.4–64; 23)

32.6 (14.2–97.2; 36)

 CSF TP, > 100 mg/dl

Samples

0/98 (0%)

0/87 (0%)

0/9 (0%)

0/28 (0%)

0/23 (0%)

0/0 (0%)

 CSF TP, elevated (> 45 mg/dl)

Samples

22/98 (22.4%)

21/87 (24.1%)

1/9 (11.1%)

10/27 (37%)

1/25 (4%)

10/35 (28.6%)

 CSF TP, if elevated (> 45 mg/dl)

mg/dl

58.3 (46.3–97.2; 22)

60 (46.3–97.2; 21)

56.6 (56.6–56.6; 1)

57 (46.3–89; 10)

64 (64–64; 1)

57 (49–97.2; 10)

 CSF TP, elevated (age–adapteda)

Samples

59/98 (60.2%)

54/87 (62.1%)

3/9 (33.3%)

55/85 (64.7%)

2/11 (18.2%)

52/77 (67.5%)

 CSF TP, if elevated (age-adapteda)

mg/dl

41 (26.1–97.2; 59)

42.6 (26.1–97.2; 54)

40 (31.7–56.6; 3)

42 (26.1–97.2; 55)

38.7 (28.4–49; 2)

42.6 (26.1–97.2; 52)

CSF l-lactate

 CSF l-lactate, elevated

samples

22/72 (30.6%)

20/66 (30.3%)

2/6 (33.3%)

10/22 (45.5%)

4/21 (19%)

6/23 (26.1%)

 CSF l-lactate, all LPs

mmol/l

1.6 (0.9–2.83; 70)

1.6 (0.9–2.83; 64)

1.7 (1–2.11; 6)

1.74 (1–2.6; 22)

1.5 (0.97–2.56; 19)

1.57 (0.9–2.83 ;23)

 CSF lactate, if elevated

mmol/l

2 (1.8–2.83; 22)

2 (1.8–2.83; 20)

2.01 (1.9–2.11; 2)

2.04 (1.38–2.6; 6)

1.53 (1.53–1.53; 1)

1.57 (1.1–2.83; 7)

 CSF l-lactate, > 3 mmol/l

samples

0/70 (0%)

0/64 (0%)

0/6 (0%)

0/22 (0%)

0/19 (0%)

0/23 (0%)

  1. Ratios and concentrations are given as median (with range and sample numbers in brackets)
  2. Alb albumin, BCB blood–CSF barrier, LP lumbar puncture, QAlb CSF/serum albumin ratio, TP total protein
  3. aAge-dependent upper reference limits adapted from [47] (0.25 g/l for patients 0.5 months–≤ 6 years at the time of LP, 0.28 g/l > 6–≤ 12 years, 0.34 g/l for > 12–≤ 18 years)
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094